<DOC>
	<DOCNO>NCT01457456</DOCNO>
	<brief_summary>Development new MS-based biomarker early sensitive diagnosis Morquio disease plasma</brief_summary>
	<brief_title>Biomarker Morquio Disease</brief_title>
	<detailed_description>Morquio syndrome ( mucopolysaccharidosis type IV ; MPS IV ) mucopolysaccharide stor-age disease exist two form ( Morquio syndromes A B ) occur deficiency enzymes N-acetyl-galactosamine-6-sulfatase beta-galactosidase , respectively . A deficiency either enzyme lead accumulation mucopolysaccharide body , abnormal skeletal development , additional symptom . In case , individual Morquio syndrome normal intelligence . The clinical feature MPS IV-B less severe associate MPS IV-A . Symptoms may include growth retardation , prominent low face , abnormally short neck , knees abnormally close together ( knock knee genu valgum ) , flat foot , abnormal sideways front-to-back side-to-side curvature spine ( kyphoscoliosis ) , abnormal development grow end long bone ( epiphysis ) result dwarfism , and/or prominent breast bone ( pectus carinatum ) well bell shape chest . Though CNS peripheral nerve primarily affect bone defect may result neurological symptom spinal cord compression . Hearing loss , weakness leg , and/or additional abnormality may also occur . The mucopolysaccharidoses ( MPS ) group inherit lysosomal storage disorder . Lysosomes function primary digestive unit within cell . Enzymes within lysosome break digest particular nutrient , certain carbohydrate fat . In individual MPS disorder , deficiency malfunction specific lysosomal enzyme lead abnormal accumulation certain complex carbohydrate ( mucopolysaccharide glyco-saminoglycans ) artery , skeleton , eye , joint , ear , skin and/or teeth . These accumulation may also find respiratory system , liver , spleen , central nervous system , blood , bone marrow . This accumulation eventually cause progressive damage cell , tissue , various organ system body . There several different type subtypes mucopolysaccharidosis . These disorder , one exception , inherit autosomal recessive trait vary clinical phenotype . Within clinical trial focus MPS type IV . New method , like mass-spectrometry give good chance characterize blood ( plasma ) affect patent specific metabolic alteration allow diagnose future disease earlier , high sensitivity specificity . Therefore goal study develop new biochemical marker plasma affected patient help benefit patient early diagnose thereby earlier treatment .</detailed_description>
	<mesh_term>Lysosomal Storage Diseases</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<mesh_term>Osteochondrodysplasias</mesh_term>
	<criteria>Informed consent obtain patient parent study related procedure . Patients older 12 month The patient diagnosis Morquio disease base upon biochemical and/or genetic criterion No Informed consent patient parent study related procedure . Patients young 12 month The patient diagnosis Morquio disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mucopolysaccharidoses</keyword>
	<keyword>Mucopolysaccharidosis IV</keyword>
	<keyword>Carbohydrate Metabolism , Inborn Errors</keyword>
	<keyword>Metabolism , Inborn Errors</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Lysosomal Storage Diseases</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
</DOC>